// Global Analysis Archive
According to the source, Merck China leadership expects the industry to move from AI-assisted discovery to fully AI-designed compounds entering pipelines by 2026, with China potentially approving a first AI-designed drug as early as next year. The development signals a strategic shift in drug R&D, raising stakes around regulatory frameworks, data governance, and competitive IP positioning.
The source reports that President Donald Trump increased tariffs on certain South Korean imports to 25%, arguing Seoul’s legislature has not enacted a bilateral trade agreement. The move heightens supply-chain and alliance-management risks while adding uncertainty amid ongoing US legal scrutiny of tariff policy.
A Hong Kong co-led global trial reported by SCMP found 55% of previously untreated advanced ALK-positive NSCLC patients on lorlatinib had no disease progression at seven years, versus 3% on crizotinib. The findings support a strategic shift toward managing certain advanced cancers as chronic conditions, with implications for diagnostics, reimbursement, and long-term care capacity.
According to the source, Merck China leadership expects the industry to move from AI-assisted discovery to fully AI-designed compounds entering pipelines by 2026, with China potentially approving a first AI-designed drug as early as next year. The development signals a strategic shift in drug R&D, raising stakes around regulatory frameworks, data governance, and competitive IP positioning.
The source reports that President Donald Trump increased tariffs on certain South Korean imports to 25%, arguing Seoul’s legislature has not enacted a bilateral trade agreement. The move heightens supply-chain and alliance-management risks while adding uncertainty amid ongoing US legal scrutiny of tariff policy.
A Hong Kong co-led global trial reported by SCMP found 55% of previously untreated advanced ALK-positive NSCLC patients on lorlatinib had no disease progression at seven years, versus 3% on crizotinib. The findings support a strategic shift toward managing certain advanced cancers as chronic conditions, with implications for diagnostics, reimbursement, and long-term care capacity.
| ID | Title | Category | Date | Views | |
|---|---|---|---|---|---|
| RPT-239 | China Poised for Early Approval of Fully AI-Designed Drug as Pharma R&D Shifts to AI-Native Compounds | China | 2026-01-27 | 0 | ACCESS » |
| RPT-224 | Trump Raises Tariffs on South Korean Autos, Lumber and Pharma to 25%, Citing Deal Implementation Gaps | US-South Korea | 2026-01-26 | 1 | ACCESS » |
| RPT-4999 | CUHK-Led Trial Signals Long-Term Control for ALK-Positive Lung Cancer with Lorlatinib | Hong Kong | 2025-08-17 | 0 | ACCESS » |